Clearside Biomedical stock hits 52-week low at $0.79

Published 03/03/2025, 21:46
Clearside Biomedical stock hits 52-week low at $0.79

Clearside Biomedical Inc . (NASDAQ:CLSD) stock has reached a 52-week low, touching down at $0.79. According to InvestingPro data, while the company maintains strong liquidity with assets exceeding short-term obligations, it’s currently burning through cash at a concerning rate. This latest price level reflects a significant downturn for the company, which specializes in developing innovative treatments for blinding diseases. Over the past year, Clearside Biomedical has seen its stock value decrease by 40.43%, indicating a challenging period for the biotech firm. Investors are closely monitoring the company’s performance and potential market catalysts that may influence its stock trajectory in the coming months. InvestingPro analysis reveals significant stock price volatility, with 4 analysts revising earnings upward for the upcoming period. For deeper insights into CLSD’s financial health and growth prospects, including 6 additional exclusive ProTips, check out the comprehensive Pro Research Report available on InvestingPro.

In other recent news, Clearside Biomedical, Inc. announced that the China National Medical (TASE:BLWV) Products Administration has accepted Arctic Vision’s New Drug Application for ARCATUS®, a treatment for uveitic macular edema. This development follows positive results from Arctic Vision’s Phase 3 clinical trial in China. ARCATUS®, known as XIPERE® in the U.S., is already approved in the United States, Australia, and Singapore. In another update, Clearside has reported progress in its ODYSSEY Phase 2b clinical trial for the treatment of neovascular age-related macular degeneration (wet AMD (NASDAQ:AMD)). The trial’s subgroup analyses are shaping the upcoming Phase 3 clinical development for CLS-AX, indicating potential for a durable treatment option. Notably, 67% of patients in the CLS-AX arm did not require additional treatment for six months. Clearside’s proprietary SCS Microinjector® played a key role in delivering the treatment effectively. The company is preparing for further presentations on the CLS-AX program at upcoming medical meetings.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.